|  Formulas
for Success in the Elderly: New Solutions for the
Treatment of Asthma
This
program was presented at a live symposium on November
14, 2002 at Senior Care Pharmacy 2002, ASCP's 33rd
Annual Meeting and Exhibition of American Society
of Consultant Pharmacists. If you attended the live
symposium, you are not eligible to receive continuing
pharmaceutical education credit through this program.
This program was supported by an educational grant
from Forest Pharmaceuticals, Inc.
This
program #203-999-02-441-H01 has been approved
for 2.0 contact hours (0.2 CEUs) of continuing pharmaceutical
education for pharmacists who participate in and evaluate
the program in its entirety. This program is valid
through November 14, 2005.
|
Management
guidelines for asthma are similar for all ages, yet
epidemiological data support that the elderly carry
a disproportionate burden of the mortality and morbidity
associated with asthma. In fact, the death rate due
to asthma among the elderly is 14 times higher than
that of the population in the 18-35 age range.
In light of these statistics, it is apparent that
appropriate diagnosis and treatment of asthma in the
elderly have significant public health implications.
The healthcare professional must be aware of special
considerations when treating an elderly person, such
as differential diagnosis of asthma among other pulmonary
disorders and attention to drug interactions, coexistent
diseases, and enhancing compliance. This program is
designed to provide the pharmacist with an overview
of these challenges; an understanding of the pathophysiology
of asthma in the elderly, including the role of the
distal airways; and an awareness of the advantages
and disadvantages of currently available asthma therapies,
with a focus on new formulations that may benefit
the elderly by targeting all airways through delivery
systems that are cost-effective and easy to administer. |
Click
here to begin the course
Educational
Objectives
On completion of this activity the participant should
be able to: |
| |
Identify current challenges and obstacles to the diagnosis
of asthma in the elderly |
| |
Discuss
overall approaches for optimizing treatment of asthma
in the elderly |
| |
Explore
age-specific pathophysiological components of asthma,
including the role of the small airways |
| |
Review
new therapeutic options available for the treatment
of asthma and discuss how they may benefit the elderly
in the long-term care setting. |
| Agenda |
| |
Introduction
George Bensch, MD
Program Chairperson
Director of Allergy, Asthma and Immunology
San Joaquin General Hospital
San Joaquin, California |
| |
Current
Challenges to Optimizing Treatment of Asthma in the
Elderly
Neil R. MacIntyre, Jr, MD
Medical Director of Respiratory Care Services
Professor of Medicine
Duke University Medical Center
Durham, North Carolina |
| |
Pathophysiology
of Asthma: Age-Specific Considerations
Monica Kraft, MD
Associate Professor of Medicine
University of Colorado Health Sciences Center
National Jewish Research and Medical Center
Denver, Colorado |
| |
Effective
Therapies for the Treatment of Asthma in the Elderly
George Bensch, MD
Director of Allergy, Asthma and Immunology
San Joaquin General Hospital
San Joaquin, California |
Disclosures:
| Neil MacIntyre |
(nothing to disclose) |
| |
|
Monica Kraft
|
Merck: Research grant, Speakers bureau
GlaxoSmithKline: Speakers bureau
Forest: Speakers bureau
Aventis: Consultant
Novartis: Consultant |
| |
|
| George Bench |
AstraZeneca: Speaker, Research, Consultant
Forest: Speaker, Research, Consultant
GlaxoSmithKline: Speaker, Research, Consultant
Protein Design Labs: Research
Wyeth: Research
Immunex: Research |
 |
The American Society of
Consultant Pharmacists (ASCP) is approved by the American
Council on Pharmaceutical Education (ACPE as a provider
of continuing pharmaceutical education.
This program #203-999-02-441-H01 has been approved
for 2.0 contact hours (0.2 CEUs) of continuing pharmaceutical
education for pharmacists who participate in and evaluate
the program in its entirety. This program is valid
through November 14, 2005. |
This program is supported by an unrestricted educational
grant from Forest Pharmaceuticals, Inc.
|
